Lindsey Shapiro, PhD,  science writer—

A new review study found limited evidence that exercise may be beneficial in slowing Parkinson’s disease progression, as assessed by behavioral, neurochemical, and imaging measures. Yet no particular exercise type emerged as superior to the others for Parkinson’s patients, although evidence hinted that a higher intensity training with…

Parkinson’s disease patients in Japan reported a general worsening of their symptoms and less time spent out of the house during the COVID-19 pandemic in a recent survey study. As a result, caregivers reported an increased burden that was accompanied by more frustration and fatigue. “For future emergency control…

People with post-traumatic stress disorder (PTSD) were found to be at a higher risk of Parkinson’s disease or related neurodegenerative conditions, a small meta-analysis suggests. “The small number of studies to date provide preliminary evidence of an association between mid- to late-life onset PTSD and subsequent development of [Parkinson’s]…

Supernus Pharmaceuticals plans to resubmit its application seeking approval of SPN-830, its apomorphine infusion pump for people with Parkinson’s disease, to the U.S. Food and Drug Administration (FDA) by the end of this year. The decision comes after a meeting with the FDA last month at which…

Gain Therapeutics has been awarded about $2.8 million to advance the development of GT-02287, its lead therapeutic candidate for GBA1-associated Parkinson’s disease. Innosuisse, the Swiss Innovation Agency, granted the 2.5 million Swiss francs to the company under its Swiss Accelerator program, which provides funding for new…

NeuroOne Medical Technologies‘ Evo stereoelectroencephalography (sEEG) electrodes for measuring or stimulating brain activity in people with neurological diseases like Parkinson’s disease or epilepsy are now available commercially in the U.S. The electrodes were approved by the U.S. Food and Drug Administration (FDA) in October for less than…

People newly diagnosed with Parkinson’s disease were found to have significantly lower blood levels of the argonaute 2 (AGO2) protein relative to healthy adults, according to a recent biomarker study conducted by NeuroSense Therapeutics. In people with amyotrophic lateral sclerosis (ALS), the company’s PrimeC treatment candidate previously…

IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast…

Parkinson’s disease patients treated with prasinezumab for three years — as part of a long-term extension of the Phase 2 PASADENA clinical trial — were shown to be at a lower risk of motor symptom progression and motor complications than patients who started treatment a year later, according to…

Physiotherapy, and mind-body exercise particularly, can meaningfully ease motor symptoms of Parkinson’s disease, a recent meta-analysis of clinical trial data involving more than 2,500 people reported. Mind-body exercise refers to practices that focus on the connection between the body, breath, and the mind, such as yoga, tai chi, or…